nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—PTGS1—kidney cancer	0.542	0.636	CbGaD
Nepafenac—PTGS2—kidney cancer	0.31	0.364	CbGaD
Nepafenac—Ulcerative keratitis—Erlotinib—kidney cancer	0.00487	0.0454	CcSEcCtD
Nepafenac—Impaired healing—Temsirolimus—kidney cancer	0.00396	0.0369	CcSEcCtD
Nepafenac—Impaired healing—Everolimus—kidney cancer	0.00295	0.0275	CcSEcCtD
Nepafenac—Impaired healing—Sunitinib—kidney cancer	0.00246	0.0229	CcSEcCtD
Nepafenac—Punctate keratitis—Capecitabine—kidney cancer	0.00232	0.0217	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—ANXA4—kidney cancer	0.00212	0.0627	CbGpPWpGaD
Nepafenac—Keratitis—Erlotinib—kidney cancer	0.0019	0.0177	CcSEcCtD
Nepafenac—Scab—Capecitabine—kidney cancer	0.00185	0.0172	CcSEcCtD
Nepafenac—Cataract—Temsirolimus—kidney cancer	0.0018	0.0168	CcSEcCtD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—ANXA4—kidney cancer	0.00168	0.0498	CbGpPWpGaD
Nepafenac—Blood pressure increased—Pazopanib—kidney cancer	0.00161	0.015	CcSEcCtD
Nepafenac—Eye pruritus—Paclitaxel—kidney cancer	0.0016	0.0149	CcSEcCtD
Nepafenac—Diabetes mellitus—Temsirolimus—kidney cancer	0.00143	0.0133	CcSEcCtD
Nepafenac—Cataract—Everolimus—kidney cancer	0.00134	0.0125	CcSEcCtD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—KEAP1—kidney cancer	0.00128	0.0378	CbGpPWpGaD
Nepafenac—Visual acuity reduced—Paclitaxel—kidney cancer	0.0012	0.0112	CcSEcCtD
Nepafenac—Photophobia—Vinblastine—kidney cancer	0.0012	0.0112	CcSEcCtD
Nepafenac—Lacrimation increased—Sunitinib—kidney cancer	0.00116	0.0108	CcSEcCtD
Nepafenac—Dermatitis atopic—Gemcitabine—kidney cancer	0.00115	0.0108	CcSEcCtD
Nepafenac—Dry eye—Erlotinib—kidney cancer	0.00114	0.0106	CcSEcCtD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT8—kidney cancer	0.00113	0.0334	CbGpPWpGaD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—ANXA2—kidney cancer	0.00111	0.0329	CbGpPWpGaD
Nepafenac—Blood pressure increased—Sorafenib—kidney cancer	0.00111	0.0103	CcSEcCtD
Nepafenac—Keratitis—Paclitaxel—kidney cancer	0.0011	0.0103	CcSEcCtD
Nepafenac—Blood pressure increased—Sunitinib—kidney cancer	0.00106	0.00992	CcSEcCtD
Nepafenac—Diabetes mellitus—Everolimus—kidney cancer	0.00106	0.00991	CcSEcCtD
Nepafenac—Visual acuity reduced—Capecitabine—kidney cancer	0.000987	0.0092	CcSEcCtD
Nepafenac—Dermatitis atopic—Paclitaxel—kidney cancer	0.000966	0.00901	CcSEcCtD
Nepafenac—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS1—kidney cancer	0.000934	0.0276	CbGpPWpGaD
Nepafenac—Keratitis—Capecitabine—kidney cancer	0.000905	0.00843	CcSEcCtD
Nepafenac—Sinusitis—Temsirolimus—kidney cancer	0.000899	0.00838	CcSEcCtD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—ANXA2—kidney cancer	0.000884	0.0262	CbGpPWpGaD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—FOSL1—kidney cancer	0.000874	0.0259	CbGpPWpGaD
Nepafenac—Eye irritation—Paclitaxel—kidney cancer	0.000838	0.00781	CcSEcCtD
Nepafenac—Eye disorder—Temsirolimus—kidney cancer	0.000804	0.00749	CcSEcCtD
Nepafenac—Angiopathy—Temsirolimus—kidney cancer	0.000781	0.00728	CcSEcCtD
Nepafenac—Immune system disorder—Temsirolimus—kidney cancer	0.000777	0.00724	CcSEcCtD
Nepafenac—Lacrimation increased—Paclitaxel—kidney cancer	0.000776	0.00723	CcSEcCtD
Nepafenac—Eye disorder—Pazopanib—kidney cancer	0.000758	0.00706	CcSEcCtD
Nepafenac—Angiopathy—Pazopanib—kidney cancer	0.000736	0.00686	CcSEcCtD
Nepafenac—PTGS2—Overview of nanoparticle effects—PTGS1—kidney cancer	0.000732	0.0216	CbGpPWpGaD
Nepafenac—Blood pressure increased—Paclitaxel—kidney cancer	0.000715	0.00667	CcSEcCtD
Nepafenac—Eye irritation—Capecitabine—kidney cancer	0.000687	0.00641	CcSEcCtD
Nepafenac—Sinusitis—Everolimus—kidney cancer	0.000669	0.00623	CcSEcCtD
Nepafenac—Vision blurred—Pazopanib—kidney cancer	0.000665	0.0062	CcSEcCtD
Nepafenac—Dry eye—Paclitaxel—kidney cancer	0.000661	0.00616	CcSEcCtD
Nepafenac—Hypertension—Temsirolimus—kidney cancer	0.000647	0.00603	CcSEcCtD
Nepafenac—Lacrimation—Doxorubicin—kidney cancer	0.000643	0.006	CcSEcCtD
Nepafenac—Ketorolac—PTGS1—kidney cancer	0.000639	0.083	CrCbGaD
Nepafenac—Lacrimation increased—Capecitabine—kidney cancer	0.000637	0.00594	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.000633	0.0059	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—ANXA1—kidney cancer	0.000627	0.0186	CbGpPWpGaD
Nepafenac—Cataract—Capecitabine—kidney cancer	0.000617	0.00575	CcSEcCtD
Nepafenac—Bromfenac—PTGS1—kidney cancer	0.000613	0.0795	CrCbGaD
Nepafenac—Hypertension—Pazopanib—kidney cancer	0.000609	0.00568	CcSEcCtD
Nepafenac—PTGS2—Eicosanoid Synthesis—PTGS1—kidney cancer	0.000607	0.018	CbGpPWpGaD
Nepafenac—Nervous system disorder—Temsirolimus—kidney cancer	0.0006	0.00559	CcSEcCtD
Nepafenac—Eye disorder—Everolimus—kidney cancer	0.000598	0.00558	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.000597	0.00556	CcSEcCtD
Nepafenac—Skin disorder—Temsirolimus—kidney cancer	0.000594	0.00553	CcSEcCtD
Nepafenac—Dry mouth—Pazopanib—kidney cancer	0.000588	0.00548	CcSEcCtD
Nepafenac—Blood pressure increased—Capecitabine—kidney cancer	0.000587	0.00547	CcSEcCtD
Nepafenac—Keratitis—Doxorubicin—kidney cancer	0.000583	0.00544	CcSEcCtD
Nepafenac—Angiopathy—Everolimus—kidney cancer	0.000581	0.00541	CcSEcCtD
Nepafenac—Immune system disorder—Everolimus—kidney cancer	0.000578	0.00539	CcSEcCtD
Nepafenac—Eye disorder—Erlotinib—kidney cancer	0.000577	0.00538	CcSEcCtD
Nepafenac—Eye pain—Paclitaxel—kidney cancer	0.000575	0.00536	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOSL1—kidney cancer	0.000565	0.0167	CbGpPWpGaD
Nepafenac—Nervous system disorder—Pazopanib—kidney cancer	0.000565	0.00526	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—ROS1—kidney cancer	0.000563	0.0166	CbGpPWpGaD
Nepafenac—Skin disorder—Pazopanib—kidney cancer	0.000559	0.00521	CcSEcCtD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—kidney cancer	0.000551	0.0163	CbGpPWpGaD
Nepafenac—Dry eye—Capecitabine—kidney cancer	0.000542	0.00505	CcSEcCtD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000541	0.016	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.000528	0.00492	CcSEcCtD
Nepafenac—Vision blurred—Everolimus—kidney cancer	0.000525	0.00489	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—ACY1—kidney cancer	0.000524	0.0155	CbGpPWpGaD
Nepafenac—Tiaprofenic acid—PTGS1—kidney cancer	0.000521	0.0676	CrCbGaD
Nepafenac—Dermatitis atopic—Doxorubicin—kidney cancer	0.000511	0.00476	CcSEcCtD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—PTGS1—kidney cancer	0.000508	0.015	CbGpPWpGaD
Nepafenac—Angiopathy—Sorafenib—kidney cancer	0.000504	0.0047	CcSEcCtD
Nepafenac—Immune system disorder—Sorafenib—kidney cancer	0.000502	0.00468	CcSEcCtD
Nepafenac—Eye disorder—Sunitinib—kidney cancer	0.0005	0.00466	CcSEcCtD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—ANXA1—kidney cancer	0.000498	0.0147	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Pazopanib—kidney cancer	0.000497	0.00463	CcSEcCtD
Nepafenac—Diabetes mellitus—Capecitabine—kidney cancer	0.00049	0.00457	CcSEcCtD
Nepafenac—Angiopathy—Sunitinib—kidney cancer	0.000485	0.00452	CcSEcCtD
Nepafenac—Magnesium salicylate—PTGS1—kidney cancer	0.000484	0.0629	CrCbGaD
Nepafenac—Hypertension—Vinblastine—kidney cancer	0.000483	0.0045	CcSEcCtD
Nepafenac—Immune system disorder—Sunitinib—kidney cancer	0.000483	0.0045	CcSEcCtD
Nepafenac—Hypertension—Everolimus—kidney cancer	0.000481	0.00448	CcSEcCtD
Nepafenac—Fenbufen—PTGS1—kidney cancer	0.000474	0.0615	CrCbGaD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—EIF4EBP1—kidney cancer	0.000473	0.014	CbGpPWpGaD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—HSPB1—kidney cancer	0.000473	0.014	CbGpPWpGaD
Nepafenac—Eye pain—Capecitabine—kidney cancer	0.000472	0.0044	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000471	0.00439	CcSEcCtD
Nepafenac—Dry mouth—Everolimus—kidney cancer	0.000464	0.00432	CcSEcCtD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUNB—kidney cancer	0.000459	0.0136	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000455	0.00424	CcSEcCtD
Nepafenac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—kidney cancer	0.000451	0.0133	CbGpPWpGaD
Nepafenac—Hypersensitivity—Temsirolimus—kidney cancer	0.00045	0.0042	CcSEcCtD
Nepafenac—Nervous system disorder—Everolimus—kidney cancer	0.000446	0.00416	CcSEcCtD
Nepafenac—Skin disorder—Everolimus—kidney cancer	0.000442	0.00412	CcSEcCtD
Nepafenac—Arthritis—Capecitabine—kidney cancer	0.000438	0.00409	CcSEcCtD
Nepafenac—Pruritus—Temsirolimus—kidney cancer	0.000433	0.00403	CcSEcCtD
Nepafenac—Nervous system disorder—Erlotinib—kidney cancer	0.00043	0.00401	CcSEcCtD
Nepafenac—Skin disorder—Erlotinib—kidney cancer	0.000426	0.00397	CcSEcCtD
Nepafenac—Mebendazole—CYP1A1—kidney cancer	0.000425	0.0551	CrCbGaD
Nepafenac—Hypertension—Sorafenib—kidney cancer	0.000418	0.00389	CcSEcCtD
Nepafenac—Salsalate—PTGS1—kidney cancer	0.000412	0.0535	CrCbGaD
Nepafenac—Lacrimation increased—Doxorubicin—kidney cancer	0.000411	0.00383	CcSEcCtD
Nepafenac—Angiopathy—Vincristine—kidney cancer	0.00041	0.00382	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000409	0.00381	CcSEcCtD
Nepafenac—Pruritus—Pazopanib—kidney cancer	0.000407	0.0038	CcSEcCtD
Nepafenac—Dizziness—Temsirolimus—kidney cancer	0.000404	0.00377	CcSEcCtD
Nepafenac—Dry mouth—Sorafenib—kidney cancer	0.000403	0.00375	CcSEcCtD
Nepafenac—Hypertension—Sunitinib—kidney cancer	0.000402	0.00375	CcSEcCtD
Nepafenac—PTGS2—S1P1 pathway—KDR—kidney cancer	0.000401	0.0119	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000394	0.00367	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Everolimus—kidney cancer	0.000393	0.00366	CcSEcCtD
Nepafenac—Angiopathy—Gemcitabine—kidney cancer	0.000389	0.00363	CcSEcCtD
Nepafenac—Vomiting—Temsirolimus—kidney cancer	0.000389	0.00362	CcSEcCtD
Nepafenac—Dry mouth—Sunitinib—kidney cancer	0.000388	0.00361	CcSEcCtD
Nepafenac—Immune system disorder—Gemcitabine—kidney cancer	0.000387	0.00361	CcSEcCtD
Nepafenac—Nervous system disorder—Sorafenib—kidney cancer	0.000387	0.00361	CcSEcCtD
Nepafenac—Skin disorder—Sorafenib—kidney cancer	0.000383	0.00357	CcSEcCtD
Nepafenac—Headache—Temsirolimus—kidney cancer	0.000383	0.00357	CcSEcCtD
Nepafenac—Dizziness—Pazopanib—kidney cancer	0.000381	0.00355	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000379	0.00353	CcSEcCtD
Nepafenac—Sinusitis—Paclitaxel—kidney cancer	0.000375	0.0035	CcSEcCtD
Nepafenac—Nervous system disorder—Sunitinib—kidney cancer	0.000373	0.00347	CcSEcCtD
Nepafenac—Skin disorder—Sunitinib—kidney cancer	0.000369	0.00344	CcSEcCtD
Nepafenac—Vomiting—Pazopanib—kidney cancer	0.000366	0.00341	CcSEcCtD
Nepafenac—Ketorolac—PTGS2—kidney cancer	0.000365	0.0474	CrCbGaD
Nepafenac—Nausea—Temsirolimus—kidney cancer	0.000363	0.00338	CcSEcCtD
Nepafenac—Headache—Pazopanib—kidney cancer	0.000361	0.00336	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—PTGS2—kidney cancer	0.000353	0.0105	CbGpPWpGaD
Nepafenac—Bromfenac—PTGS2—kidney cancer	0.00035	0.0455	CrCbGaD
Nepafenac—Dry eye—Doxorubicin—kidney cancer	0.000349	0.00326	CcSEcCtD
Nepafenac—Nausea—Pazopanib—kidney cancer	0.000342	0.00319	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000341	0.00318	CcSEcCtD
Nepafenac—Fenoprofen—PTGS1—kidney cancer	0.00034	0.0442	CrCbGaD
Nepafenac—Hypertension—Vincristine—kidney cancer	0.00034	0.00317	CcSEcCtD
Nepafenac—PTGS2—Arachidonic acid metabolism—PTGS1—kidney cancer	0.000337	0.00998	CbGpPWpGaD
Nepafenac—Hypersensitivity—Vinblastine—kidney cancer	0.000336	0.00313	CcSEcCtD
Nepafenac—Eye disorder—Paclitaxel—kidney cancer	0.000336	0.00313	CcSEcCtD
Nepafenac—Hypersensitivity—Everolimus—kidney cancer	0.000335	0.00312	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000328	0.00306	CcSEcCtD
Nepafenac—Angiopathy—Paclitaxel—kidney cancer	0.000326	0.00304	CcSEcCtD
Nepafenac—Immune system disorder—Paclitaxel—kidney cancer	0.000324	0.00302	CcSEcCtD
Nepafenac—Hypertension—Gemcitabine—kidney cancer	0.000322	0.003	CcSEcCtD
Nepafenac—Pruritus—Everolimus—kidney cancer	0.000322	0.003	CcSEcCtD
Nepafenac—Diabetes mellitus—Doxorubicin—kidney cancer	0.000316	0.00294	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000316	0.00294	CcSEcCtD
Nepafenac—Mefenamic acid—PTGS1—kidney cancer	0.000316	0.041	CrCbGaD
Nepafenac—Nervous system disorder—Vincristine—kidney cancer	0.000315	0.00294	CcSEcCtD
Nepafenac—Pruritus—Erlotinib—kidney cancer	0.00031	0.00289	CcSEcCtD
Nepafenac—Eye pain—Doxorubicin—kidney cancer	0.000304	0.00284	CcSEcCtD
Nepafenac—Dizziness—Vinblastine—kidney cancer	0.000302	0.00281	CcSEcCtD
Nepafenac—Dizziness—Everolimus—kidney cancer	0.000301	0.0028	CcSEcCtD
Nepafenac—Nervous system disorder—Gemcitabine—kidney cancer	0.000299	0.00279	CcSEcCtD
Nepafenac—Tiaprofenic acid—PTGS2—kidney cancer	0.000298	0.0387	CrCbGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUNB—kidney cancer	0.000297	0.00879	CbGpPWpGaD
Nepafenac—Skin disorder—Gemcitabine—kidney cancer	0.000296	0.00276	CcSEcCtD
Nepafenac—Vision blurred—Paclitaxel—kidney cancer	0.000295	0.00275	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CD34—kidney cancer	0.000294	0.0087	CbGpPWpGaD
Nepafenac—PTGS1—Eicosanoid Synthesis—PTGS2—kidney cancer	0.000293	0.00867	CbGpPWpGaD
Nepafenac—Hypersensitivity—Sorafenib—kidney cancer	0.000291	0.00271	CcSEcCtD
Nepafenac—Vomiting—Vinblastine—kidney cancer	0.00029	0.00271	CcSEcCtD
Nepafenac—Dizziness—Erlotinib—kidney cancer	0.00029	0.0027	CcSEcCtD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—kidney cancer	0.00029	0.00858	CbGpPWpGaD
Nepafenac—Vomiting—Everolimus—kidney cancer	0.000289	0.00269	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—ALDH1A1—kidney cancer	0.000287	0.0085	CbGpPWpGaD
Nepafenac—Headache—Vinblastine—kidney cancer	0.000286	0.00267	CcSEcCtD
Nepafenac—Headache—Everolimus—kidney cancer	0.000285	0.00266	CcSEcCtD
Nepafenac—Hypersensitivity—Sunitinib—kidney cancer	0.00028	0.00261	CcSEcCtD
Nepafenac—Pruritus—Sorafenib—kidney cancer	0.000279	0.0026	CcSEcCtD
Nepafenac—Vomiting—Erlotinib—kidney cancer	0.000279	0.0026	CcSEcCtD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—EGR1—kidney cancer	0.000278	0.00822	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Vincristine—kidney cancer	0.000277	0.00259	CcSEcCtD
Nepafenac—Magnesium salicylate—PTGS2—kidney cancer	0.000277	0.0359	CrCbGaD
Nepafenac—Eye disorder—Capecitabine—kidney cancer	0.000275	0.00257	CcSEcCtD
Nepafenac—Headache—Erlotinib—kidney cancer	0.000275	0.00256	CcSEcCtD
Nepafenac—PTGS1—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000274	0.0081	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—SCARB1—kidney cancer	0.000273	0.00808	CbGpPWpGaD
Nepafenac—Nausea—Vinblastine—kidney cancer	0.000271	0.00253	CcSEcCtD
Nepafenac—Fenbufen—PTGS2—kidney cancer	0.000271	0.0352	CrCbGaD
Nepafenac—Nausea—Everolimus—kidney cancer	0.00027	0.00252	CcSEcCtD
Nepafenac—Hypertension—Paclitaxel—kidney cancer	0.00027	0.00252	CcSEcCtD
Nepafenac—Pruritus—Sunitinib—kidney cancer	0.000269	0.0025	CcSEcCtD
Nepafenac—Angiopathy—Capecitabine—kidney cancer	0.000267	0.00249	CcSEcCtD
Nepafenac—Immune system disorder—Capecitabine—kidney cancer	0.000266	0.00248	CcSEcCtD
Nepafenac—Hypersensitivity—Dactinomycin—kidney cancer	0.000265	0.00247	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000264	0.00246	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000263	0.00245	CcSEcCtD
Nepafenac—Dizziness—Sorafenib—kidney cancer	0.000261	0.00243	CcSEcCtD
Nepafenac—Nausea—Erlotinib—kidney cancer	0.000261	0.00243	CcSEcCtD
Nepafenac—Dry mouth—Paclitaxel—kidney cancer	0.00026	0.00243	CcSEcCtD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—kidney cancer	0.000253	0.0075	CbGpPWpGaD
Nepafenac—Dizziness—Sunitinib—kidney cancer	0.000251	0.00234	CcSEcCtD
Nepafenac—Vomiting—Sorafenib—kidney cancer	0.000251	0.00234	CcSEcCtD
Nepafenac—Nervous system disorder—Paclitaxel—kidney cancer	0.00025	0.00233	CcSEcCtD
Nepafenac—Skin disorder—Paclitaxel—kidney cancer	0.000248	0.00231	CcSEcCtD
Nepafenac—Headache—Sorafenib—kidney cancer	0.000247	0.0023	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—kidney cancer	0.000245	0.00725	CbGpPWpGaD
Nepafenac—Vision blurred—Capecitabine—kidney cancer	0.000242	0.00225	CcSEcCtD
Nepafenac—Vomiting—Sunitinib—kidney cancer	0.000242	0.00225	CcSEcCtD
Nepafenac—Headache—Sunitinib—kidney cancer	0.000238	0.00222	CcSEcCtD
Nepafenac—Hypersensitivity—Vincristine—kidney cancer	0.000237	0.00221	CcSEcCtD
Nepafenac—Salsalate—PTGS2—kidney cancer	0.000235	0.0306	CrCbGaD
Nepafenac—Nausea—Sorafenib—kidney cancer	0.000234	0.00219	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	0.000232	0.00688	CbGpPWpGaD
Nepafenac—Vomiting—Dactinomycin—kidney cancer	0.000229	0.00213	CcSEcCtD
Nepafenac—Diclofenac—PTGS1—kidney cancer	0.000227	0.0294	CrCbGaD
Nepafenac—Mebendazole—ABCB1—kidney cancer	0.000226	0.0293	CrCbGaD
Nepafenac—Nausea—Sunitinib—kidney cancer	0.000226	0.0021	CcSEcCtD
Nepafenac—Hypertension—Capecitabine—kidney cancer	0.000222	0.00206	CcSEcCtD
Nepafenac—PTGS2—S1P1 pathway—VEGFA—kidney cancer	0.000221	0.00653	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.00022	0.00205	CcSEcCtD
Nepafenac—PTGS2—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000217	0.00643	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000217	0.00202	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—SCARB1—kidney cancer	0.000217	0.00642	CbGpPWpGaD
Nepafenac—Pruritus—Gemcitabine—kidney cancer	0.000216	0.00201	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—PTGS1—kidney cancer	0.000215	0.00635	CbGpPWpGaD
Nepafenac—Dry mouth—Capecitabine—kidney cancer	0.000214	0.00199	CcSEcCtD
Nepafenac—Nausea—Dactinomycin—kidney cancer	0.000214	0.00199	CcSEcCtD
Nepafenac—Dizziness—Vincristine—kidney cancer	0.000212	0.00198	CcSEcCtD
Nepafenac—PTGS2—S1P1 pathway—MAPK3—kidney cancer	0.000209	0.00618	CbGpPWpGaD
Nepafenac—Diclofenac—CYP1A1—kidney cancer	0.000207	0.0269	CrCbGaD
Nepafenac—Nervous system disorder—Capecitabine—kidney cancer	0.000205	0.00191	CcSEcCtD
Nepafenac—Vomiting—Vincristine—kidney cancer	0.000204	0.0019	CcSEcCtD
Nepafenac—Skin disorder—Capecitabine—kidney cancer	0.000203	0.0019	CcSEcCtD
Nepafenac—Headache—Vincristine—kidney cancer	0.000201	0.00188	CcSEcCtD
Nepafenac—Ketoprofen—PTGS1—kidney cancer	0.000201	0.0261	CrCbGaD
Nepafenac—PTGS2—S1P1 pathway—MAPK1—kidney cancer	0.000199	0.00588	CbGpPWpGaD
Nepafenac—Sinusitis—Doxorubicin—kidney cancer	0.000199	0.00185	CcSEcCtD
Nepafenac—Fenoprofen—PTGS2—kidney cancer	0.000195	0.0253	CrCbGaD
Nepafenac—Vomiting—Gemcitabine—kidney cancer	0.000194	0.00181	CcSEcCtD
Nepafenac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—kidney cancer	0.000192	0.00568	CbGpPWpGaD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000192	0.00568	CbGpPWpGaD
Nepafenac—Headache—Gemcitabine—kidney cancer	0.000191	0.00178	CcSEcCtD
Nepafenac—Nausea—Vincristine—kidney cancer	0.000191	0.00178	CcSEcCtD
Nepafenac—Hypersensitivity—Paclitaxel—kidney cancer	0.000188	0.00175	CcSEcCtD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—kidney cancer	0.000185	0.00548	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—SOD2—kidney cancer	0.000184	0.00546	CbGpPWpGaD
Nepafenac—Nausea—Gemcitabine—kidney cancer	0.000181	0.00169	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000181	0.00168	CcSEcCtD
Nepafenac—Pruritus—Paclitaxel—kidney cancer	0.000181	0.00168	CcSEcCtD
Nepafenac—Mefenamic acid—PTGS2—kidney cancer	0.00018	0.0234	CrCbGaD
Nepafenac—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—kidney cancer	0.00018	0.00533	CbGpPWpGaD
Nepafenac—Eye disorder—Doxorubicin—kidney cancer	0.000178	0.00165	CcSEcCtD
Nepafenac—Angiopathy—Doxorubicin—kidney cancer	0.000172	0.00161	CcSEcCtD
Nepafenac—Immune system disorder—Doxorubicin—kidney cancer	0.000172	0.0016	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—GSTT1—kidney cancer	0.000169	0.00499	CbGpPWpGaD
Nepafenac—Dizziness—Paclitaxel—kidney cancer	0.000169	0.00157	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—ANXA1—kidney cancer	0.000166	0.00493	CbGpPWpGaD
Nepafenac—PTGS1—Arachidonic acid metabolism—PTGS2—kidney cancer	0.000163	0.00482	CbGpPWpGaD
Nepafenac—Vomiting—Paclitaxel—kidney cancer	0.000162	0.00151	CcSEcCtD
Nepafenac—Headache—Paclitaxel—kidney cancer	0.00016	0.00149	CcSEcCtD
Nepafenac—Vision blurred—Doxorubicin—kidney cancer	0.000156	0.00145	CcSEcCtD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—kidney cancer	0.000155	0.00459	CbGpPWpGaD
Nepafenac—Hypersensitivity—Capecitabine—kidney cancer	0.000154	0.00144	CcSEcCtD
Nepafenac—Nausea—Paclitaxel—kidney cancer	0.000152	0.00141	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—GSTM1—kidney cancer	0.000151	0.00448	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	0.000149	0.00442	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	0.000149	0.00442	CbGpPWpGaD
Nepafenac—Pruritus—Capecitabine—kidney cancer	0.000148	0.00138	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—SOD2—kidney cancer	0.000146	0.00433	CbGpPWpGaD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—POMC—kidney cancer	0.000143	0.00423	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	0.000143	0.00423	CbGpPWpGaD
Nepafenac—Hypertension—Doxorubicin—kidney cancer	0.000143	0.00133	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	0.000142	0.00421	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	0.000142	0.00419	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.00014	0.0013	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—EGR1—kidney cancer	0.00014	0.00414	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.00014	0.00413	CbGpPWpGaD
Nepafenac—Dizziness—Capecitabine—kidney cancer	0.000138	0.00129	CcSEcCtD
Nepafenac—Dry mouth—Doxorubicin—kidney cancer	0.000138	0.00128	CcSEcCtD
Nepafenac—Vomiting—Capecitabine—kidney cancer	0.000133	0.00124	CcSEcCtD
Nepafenac—Nervous system disorder—Doxorubicin—kidney cancer	0.000132	0.00123	CcSEcCtD
Nepafenac—Headache—Capecitabine—kidney cancer	0.000131	0.00122	CcSEcCtD
Nepafenac—Skin disorder—Doxorubicin—kidney cancer	0.000131	0.00122	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	0.000131	0.00387	CbGpPWpGaD
Nepafenac—Diclofenac—PTGS2—kidney cancer	0.00013	0.0168	CrCbGaD
Nepafenac—Nausea—Capecitabine—kidney cancer	0.000124	0.00116	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	0.000123	0.00365	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—kidney cancer	0.00012	0.00355	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—GSTP1—kidney cancer	0.000117	0.00346	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—kidney cancer	0.000117	0.00345	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000117	0.00109	CcSEcCtD
Nepafenac—Ketoprofen—PTGS2—kidney cancer	0.000115	0.0149	CrCbGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	0.000113	0.00335	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—KIT—kidney cancer	0.000112	0.00333	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000111	0.00328	CbGpPWpGaD
Nepafenac—Diclofenac—ABCB1—kidney cancer	0.00011	0.0143	CrCbGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	0.000109	0.00322	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—GSTM1—kidney cancer	0.000108	0.00318	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—RELA—kidney cancer	0.000107	0.00316	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—PTGS2—kidney cancer	0.000104	0.00307	CbGpPWpGaD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—kidney cancer	0.000102	0.00303	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—CYP1A1—kidney cancer	0.000102	0.00302	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	0.000102	0.00301	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	0.000102	0.00301	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	0.0001	0.00296	CbGpPWpGaD
Nepafenac—Hypersensitivity—Doxorubicin—kidney cancer	9.95e-05	0.000927	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	9.8e-05	0.0029	CbGpPWpGaD
Nepafenac—Pruritus—Doxorubicin—kidney cancer	9.55e-05	0.00089	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	9.51e-05	0.00281	CbGpPWpGaD
Nepafenac—Carbamazepine—ABCB1—kidney cancer	9.46e-05	0.0123	CrCbGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	9.26e-05	0.00274	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—CDKN2A—kidney cancer	9.13e-05	0.0027	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ACY1—kidney cancer	8.97e-05	0.00265	CbGpPWpGaD
Nepafenac—Dizziness—Doxorubicin—kidney cancer	8.93e-05	0.000832	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CD4—kidney cancer	8.6e-05	0.00254	CbGpPWpGaD
Nepafenac—Vomiting—Doxorubicin—kidney cancer	8.58e-05	0.0008	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—RELA—kidney cancer	8.47e-05	0.0025	CbGpPWpGaD
Nepafenac—Headache—Doxorubicin—kidney cancer	8.46e-05	0.000788	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	8.35e-05	0.00247	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	8.28e-05	0.00245	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—CDKN1B—kidney cancer	8.09e-05	0.00239	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	8.09e-05	0.00239	CbGpPWpGaD
Nepafenac—Nausea—Doxorubicin—kidney cancer	8.02e-05	0.000747	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CCND1—kidney cancer	7.71e-05	0.00228	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	7.65e-05	0.00226	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PDHB—kidney cancer	7.62e-05	0.00226	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—POMC—kidney cancer	7.6e-05	0.00225	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CCBL1—kidney cancer	7.17e-05	0.00212	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ACY1—kidney cancer	7.12e-05	0.00211	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CCBL1—kidney cancer	6.79e-05	0.00201	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	6.48e-05	0.00192	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PPAT—kidney cancer	6.21e-05	0.00184	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GLIPR1—kidney cancer	6.21e-05	0.00184	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—MYC—kidney cancer	6.19e-05	0.00183	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CDKN1B—kidney cancer	6.16e-05	0.00182	CbGpPWpGaD
Nepafenac—PTGS2—Disease—AMER1—kidney cancer	6.14e-05	0.00182	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	6.14e-05	0.00182	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	6.07e-05	0.0018	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PDHB—kidney cancer	6.05e-05	0.00179	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL2—kidney cancer	6.03e-05	0.00178	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CCND1—kidney cancer	5.88e-05	0.00174	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	5.83e-05	0.00172	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—APRT—kidney cancer	5.78e-05	0.00171	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—FH—kidney cancer	5.78e-05	0.00171	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—KRAS—kidney cancer	5.72e-05	0.00169	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CCBL1—kidney cancer	5.69e-05	0.00168	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	5.65e-05	0.00167	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GPC3—kidney cancer	5.43e-05	0.00161	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CA2—kidney cancer	5.28e-05	0.00156	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ALAD—kidney cancer	5.15e-05	0.00152	CbGpPWpGaD
Nepafenac—PTGS2—Disease—GPC3—kidney cancer	5.15e-05	0.00152	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	5.15e-05	0.00152	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ST3GAL2—kidney cancer	5.03e-05	0.00149	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PPAT—kidney cancer	4.93e-05	0.00146	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GLIPR1—kidney cancer	4.93e-05	0.00146	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ALDH1A1—kidney cancer	4.91e-05	0.00145	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.87e-05	0.00144	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MAPK3—kidney cancer	4.85e-05	0.00143	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.82e-05	0.00143	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ST3GAL2—kidney cancer	4.76e-05	0.00141	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MYC—kidney cancer	4.71e-05	0.00139	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PGK1—kidney cancer	4.71e-05	0.00139	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SLC5A3—kidney cancer	4.71e-05	0.00139	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—LDHB—kidney cancer	4.62e-05	0.00137	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MAPK1—kidney cancer	4.61e-05	0.00136	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—FH—kidney cancer	4.59e-05	0.00136	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—APRT—kidney cancer	4.59e-05	0.00136	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	4.57e-05	0.00135	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	4.53e-05	0.00134	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	4.48e-05	0.00133	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PGK1—kidney cancer	4.46e-05	0.00132	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SLC5A3—kidney cancer	4.46e-05	0.00132	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SFRP2—kidney cancer	4.38e-05	0.0013	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LDHB—kidney cancer	4.38e-05	0.0013	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GPC3—kidney cancer	4.31e-05	0.00128	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CA2—kidney cancer	4.19e-05	0.00124	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	4.19e-05	0.00124	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ALAD—kidney cancer	4.09e-05	0.00121	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TCEB1—kidney cancer	4.08e-05	0.00121	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TCEB2—kidney cancer	4.08e-05	0.00121	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CA9—kidney cancer	4e-05	0.00118	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	4e-05	0.00118	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ST3GAL2—kidney cancer	3.99e-05	0.00118	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	3.99e-05	0.00118	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	3.96e-05	0.00117	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	3.91e-05	0.00116	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ALDH1A1—kidney cancer	3.9e-05	0.00115	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TP53—kidney cancer	3.87e-05	0.00115	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	3.86e-05	0.00114	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PGK1—kidney cancer	3.74e-05	0.00111	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SLC5A3—kidney cancer	3.74e-05	0.00111	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—LDHB—kidney cancer	3.67e-05	0.00108	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	3.49e-05	0.00103	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CRABP1—kidney cancer	3.41e-05	0.00101	CbGpPWpGaD
Nepafenac—PTGS2—Disease—RPL14—kidney cancer	3.32e-05	0.000982	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	3.3e-05	0.000976	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	3.21e-05	0.000949	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CA9—kidney cancer	3.18e-05	0.000941	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ITPR2—kidney cancer	3.17e-05	0.000937	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	3.14e-05	0.000928	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	3.11e-05	0.000919	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ITPR2—kidney cancer	3e-05	0.000888	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	2.96e-05	0.000877	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.92e-05	0.000863	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTT1—kidney cancer	2.89e-05	0.000854	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ACHE—kidney cancer	2.89e-05	0.000854	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SCARB1—kidney cancer	2.73e-05	0.000809	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	2.72e-05	0.000806	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CRABP1—kidney cancer	2.7e-05	0.0008	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PSMD7—kidney cancer	2.65e-05	0.000785	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	2.63e-05	0.000779	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—BCHE—kidney cancer	2.51e-05	0.000744	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PSMD7—kidney cancer	2.51e-05	0.000744	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ITPR2—kidney cancer	2.51e-05	0.000744	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SLC5A5—kidney cancer	2.48e-05	0.000735	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SLC2A1—kidney cancer	2.4e-05	0.00071	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.33e-05	0.000689	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.32e-05	0.000685	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ACHE—kidney cancer	2.29e-05	0.000678	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTT1—kidney cancer	2.29e-05	0.000678	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SLC2A1—kidney cancer	2.27e-05	0.000673	CbGpPWpGaD
Nepafenac—PTGS2—Disease—JUNB—kidney cancer	2.26e-05	0.000668	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SCARB1—kidney cancer	2.17e-05	0.000642	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PTGS1—kidney cancer	2.15e-05	0.000635	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PSMD7—kidney cancer	2.11e-05	0.000623	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.03e-05	0.000601	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTP1—kidney cancer	2e-05	0.000592	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—BCHE—kidney cancer	2e-05	0.000591	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SLC5A5—kidney cancer	1.97e-05	0.000583	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SLC2A1—kidney cancer	1.9e-05	0.000564	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ABCB1—kidney cancer	1.89e-05	0.00056	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTM1—kidney cancer	1.84e-05	0.000544	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CDKN2B—kidney cancer	1.84e-05	0.000544	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP1A1—kidney cancer	1.74e-05	0.000516	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.61e-05	0.000477	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTP1—kidney cancer	1.59e-05	0.00047	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ABCB1—kidney cancer	1.5e-05	0.000445	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HIF1A—kidney cancer	1.47e-05	0.000435	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TSC2—kidney cancer	1.47e-05	0.000434	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTM1—kidney cancer	1.46e-05	0.000432	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.43e-05	0.000424	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP1A1—kidney cancer	1.38e-05	0.000409	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—POMC—kidney cancer	1.3e-05	0.000385	CbGpPWpGaD
Nepafenac—PTGS2—Disease—KIT—kidney cancer	1.29e-05	0.000383	CbGpPWpGaD
Nepafenac—PTGS2—Disease—APC—kidney cancer	1.29e-05	0.000383	CbGpPWpGaD
Nepafenac—PTGS2—Disease—BRAF—kidney cancer	1.22e-05	0.00036	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.14e-05	0.000336	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTGS2—kidney cancer	1.04e-05	0.000307	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—POMC—kidney cancer	1.03e-05	0.000305	CbGpPWpGaD
Nepafenac—PTGS2—Disease—RAF1—kidney cancer	1.02e-05	0.000301	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERBB2—kidney cancer	1e-05	0.000297	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MTOR—kidney cancer	9.92e-06	0.000293	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CD4—kidney cancer	9.9e-06	0.000293	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CDKN1B—kidney cancer	9.31e-06	0.000275	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTEN—kidney cancer	9.04e-06	0.000267	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CTNNB1—kidney cancer	8.79e-06	0.00026	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PTEN—kidney cancer	8.57e-06	0.000254	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MAPK3—kidney cancer	7.32e-06	0.000217	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PTEN—kidney cancer	7.18e-06	0.000212	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MYC—kidney cancer	7.12e-06	0.000211	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MAPK1—kidney cancer	6.97e-06	0.000206	CbGpPWpGaD
Nepafenac—PTGS2—Disease—KRAS—kidney cancer	6.58e-06	0.000195	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CA—kidney cancer	6.38e-06	0.000189	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PIK3CA—kidney cancer	6.05e-06	0.000179	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CA—kidney cancer	5.06e-06	0.00015	CbGpPWpGaD
